Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment | Zendy

HasanTahsin Gozdas | Zendy; Oğuz Karabay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment

Author(s) -

HasanTahsin Gozdas,

Oğuz Karabay

Publication year - 2015

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.150377

Subject(s) - ototoxicity , medicine , rash , audiogram , adverse effect , gastroenterology , hepatitis , chronic hepatitis , dermatology , hearing loss , pharmacology , audiology , immunology , chemotherapy , virus , cisplatin

Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN α-2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research